ФУНДАМЕНТАЛЬНЫЕ ОСНОВЫ ПОИСКА ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ТЕРАПИИ САХАРНОГО ДИАБЕТА 2-ГО ТИПА

In the presented review the data on searching for new drugs for diabetes mellitus treatment are analyzed. These drugs are used for metabolic disorder correction leading to hyperglycemia: β-cells dysfunction, peripheral insulin resistance, increased hepatic glucose output.В обзоре проанализированы литературные данные о поиске новых препаратов для лечения сахарного диабета, направленных на коррекцию трех основных метаболических нарушений, приводящих к гипергликемии: дисфункции β-клеток, периферической инсулинорезистентности, избыточной продукции глюкозы печенью.

Influence of volume of marketable product on volume and prime-cost of auxiliary shops services

Translated from Russian (Izv. Vyssh. Uchebn. Zaved., Chern. Metall. 1987 (6) p. 142-145)SIGLEAvailable from British Library Document Supply Centre- DSC:5828.4(M--37575)T / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Ru(III) complexes with lonidamine-modified ligands

A series of bifunctional Ru(III) complexes with lonidamine-modified ligands (lonidamine is a selective inhibitor of aerobic glycolysis in cancer cells) was described. Redox properties of Ru(III) complexes were characterized by cyclic voltammetry. An easy reduction suggested a perspective for these agents as their whole mechanism of action seems to be based on activation by metal atom reduction. New compounds demonstrated a more pronounced antiproliferative potency than the parental drug; individual new agents were more cytotoxic than cisplatin. Stability studies showed an increase in the stability of complexes along with the linker length. A similar trend was noted for antiproliferative activity, cellular uptake, apoptosis induction, and thioredoxin reductase inhibition. Finally, at concentrations that did not alter water solubility, the selected new complex evoked no acute toxicity in Balb/c mice. © 2021 by the authors. Licensee MDPI, Basel, Switzerland